摘要
目的:探讨芪苈强心胶囊对冠心病合并心力衰竭患者血清脂联素(APN)、氨基末端脑钠肽前体(NT-proBNP)水平及心功能的影响。方法:将120例冠心病合并心力衰竭患者随机分为对照组和治疗组,在西医常规治疗基础上分别加用对照胶囊和芪苈强心胶囊,疗程6个月。观察治疗前后患者的心功能分级,超声心动图下测定左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)和左心室射血分数(LVEF),测量患者6 min步行距离(6-MWT),酶联免疫法测定血清APN和NT-proBNP水平变化。结果:心衰患者的血清APN和NT-proBNP水平随着美国纽约心脏协会(NYHA)分级增加而明显升高;治疗6个月后,治疗组和对照组治疗总有效率分别为91.7%和75.0%,差异有统计学意义(P<0.01)。治疗后2组患者LVEDD和LVESD均缩小,LVEF明显提高,6-MWT明显增长,血清APN和NT-proBNP水平均降低,与对照组比较,治疗组以上指标改善更为显著,差异有统计学意义(P<0.05)。结论:芪苈强心胶囊可以显著降低冠心病合并心力衰竭患者的血清APN和NT-proBNP水平,明显改善心功能。
AIM:To investigate the effects of Qili Qiangxin capsule on serum adiponectin ( APN) , serum Nterminal probrain natriuretic peptide ( NT-proBNP) and heart function in the patients of coronary heart disease combined with congestive heart failure .METHODS: One hundred and twenty patients were randomly divided into treatment group and control group , and both groups were given anti-failure routine therapy .The patients in treatment group were treated with Qili Qiangxin capsule and the patients in control group were treated with placebo .The patients in the 2 groups were given a certain dose of the drugs for 6 months.The New York Heart Association (NYHA) heart function classification, left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD),left ventricular ejection fraction (LVEF), and 6-min walking test (6-MWT) were observed before and after treatment .The levels of APN, NT-proBNP were measured by ELISA before and after treatment .RESULTS:With the increase in the class of NYHA heart function , the serum concentrations of APN and NT-proBNP in the heart failure cases increased significantly .After 6-month treatment, the effective rate in experimental group was 91.7%and that in control group was 75.0%.A significant difference was found between the 2 groups (P〈0.01).After treatment, LVEDD and LVESD in both groups were decreased significantly, and LVEF in both groups was increased significantly .The serum concentrations of APN and NT-proBNP decreased significantly (P〈0.05).6-MWT result was improved significantly.Compared with control group, more obvious effect was observed in experimental group ( P〈0.05) .CONCLUSION:Treatment with Qili Qiangxin capsule reduces the levels of APN and NT-proBNP in the patients with coronary heart disease combined with congestive heart failure .
出处
《中国病理生理杂志》
CAS
CSCD
北大核心
2014年第6期1119-1122,共4页
Chinese Journal of Pathophysiology
关键词
芪苈强心胶囊
冠心病
心力衰竭
脂联素
心功能
Qili Qiangxin capsule
Coronary heart disease
Heart failure
Adiponectin
Cardiac function